论文部分内容阅读
目的:观察雷贝拉唑三联疗法对幽门螺杆菌(HP)阳性的消化性溃疡的临床疗效。方法:将我院2012年1月—2014年2月收治的78例HP阳性的消化性溃疡患者随机分为治疗组40例和对照组38例。治疗组应用雷贝拉唑+克拉霉素+阿莫西林7天疗法,雷贝拉唑+替普瑞酮35天巩固疗法;对照组应用奥美拉唑+克拉霉素+阿莫西林7天疗法,奥美拉唑+替普瑞酮35天巩固疗法。两组治疗前、治疗6周后均进行胃镜和HP检查,评价两组之间疗效。结果:治疗组HP根除率为92.5%,与对照组(71.1%)相比较,差异具有统计学意义(P<0.05);治疗组溃疡愈合率为90.0%,总有效率为95.0%;对照组溃疡愈合率为68.4%,总有效率为78.9%。两组间溃疡愈合率以及总有效率比较差异具有统计学意义(P<0.05)。结论:雷贝拉唑三联疗法可以作为HP感染的消化性溃疡的首选疗法,值得临床推广应用。
Objective: To observe the clinical efficacy of rabeprazole triple therapy on Helicobacter pylori (HP) -positive peptic ulcer. Methods: 78 cases of HP-positive peptic ulcer patients admitted to our hospital from January 2012 to February 2014 were randomly divided into treatment group (40 cases) and control group (38 cases). Treatment group rabeprazole + clarithromycin + amoxicillin 7 days therapy, rabeprazole + teprenone 35 days consolidation therapy; the control group omeprazole + clarithromycin + amoxicillin 7 days Therapy, omeprazole + teprenone 35-day consolidation therapy. Two groups before treatment, after 6 weeks of treatment were gastroscopy and HP examination, evaluate the efficacy of the two groups. Results: The eradication rate of HP in the treatment group was 92.5%, which was significantly different from that in the control group (71.1%) (P <0.05). The healing rate of the ulcer in the treatment group was 90.0% and the total effective rate was 95.0% Ulcer healing rate was 68.4%, the total effective rate was 78.9%. The ulcer healing rate and total effective rate between the two groups were statistically significant (P <0.05). Conclusion: Rabeprazole triple therapy can be used as HP infection of peptic ulcer preferred therapy, it is worthy of clinical application.